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D uring the past 2 decades, seminal discoveries have iden-tified the genetic basis of important cardiovascular dis-eases, including hypertrophic and dilated cardiomyo-
pathy (associated with mutations in sarcomere and structural
genes),1 arrhythmogenic cardiomyopathy (associated with muta-
tions indesmosomalgenes),2 inheritedarrhythmias (associatedwith
mutations in transmembrane ionchannels genes),3 andMarfanand
related syndromes (associated with mutations in genes encoding
connective tissueelements).4Thesediscoverieshavecreatedan im-
portant role for genetic testing in the care of familieswith inherited
cardiovasculardisease,as reflected inguidelines fromnumerouspro-
fessional organizations5-11 recommending genetic testing to im-
prove the diagnosis andmanagement of patients and at-risk family
members.However,manyphysiciansmaynotbelieve that they are
fully equipped to handle complex genetic results.12,13 The Ameri-
can Heart Association14 recently outlined a statement to enhance
literacy in cardiovascular genetics forphysicians in thegenomicera.
This primer provides an overview of the role of genetic testing
for inherited cardiovascular disease via the following: highlighting
practical considerations to successfully integrate genetic testing
into clinical management and focusing on the most common tests
for inherited cardiovascular diseases, including multigene panel
tests for diagnostic testing and single-variant tests for predictive
genetic testing to determine which relatives inherited the family’s
causal variant. The general principles described apply to most
adult-onset mendelian disorders: conditions that typically mani-
fest years to decades after birth and are driven by a single gene
defect imparting a large effect.
IMPORTANCE Genetic testing is a valuable tool for managing inherited cardiovascular disease
in patients and families, including hypertrophic, dilated, and arrhythmogenic
cardiomyopathies and inherited arrhythmias. By identifying themolecular etiology of disease,
genetic testing can improve diagnostic accuracy and refine family management. However,
unique features associated with genetic testing affect the interpretation and application of
results and differentiate it from traditional laboratory-based diagnostics. Clinicians and
patients must have accurate and realistic expectations about the yield of genetic testing and
its role in management. Familiarity with the rationale, implications, benefits, and limitations
of genetic testing is essential to achieve the best possible outcomes.
OBSERVATIONS Successfully incorporating genetic testing into clinical practice requires
(1) recognizing when inherited cardiovascular disease may be present, (2) identifying
appropriate individuals in the family for testing, (3) selecting the appropriate genetic test,
(4) understanding the complexities of result interpretation, and (5) effectively
communicating the results and implications to the patient and family. Obtaining a detailed
family history is critical to identify families who will benefit from genetic testing, determine
the best strategy, and interpret results. Instead of focusing on an individual patient, genetic
testing requires consideration of the family as a unit. Consolidation of care in centers with a
high level of expertise is recommended. Clinicians without expertise in genetic testing will
benefit from establishing referral or consultative networks with experienced clinicans in
specializedmultidisciplinary clinics.
CONCLUSIONS AND RELEVANCE Genetic testing provides a foundation for transitioning to
more precise and individualizedmanagement. By distinguishing phenotypic subgroups,
identifying disease mechanisms, and focusing family care, gene-based diagnosis can improve
management. Successful integration of genetic testing into clinical practice requires
understanding of the complexities of testing and effective communication of the implications
to patients and families.
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Why Test: Clinical Uses for Genetic Testing
Genetic testingcurrently isusedmost frequently in thefollowingsitu-
ations:
1. Diagnostic testing to identify the underlying genetic etiology in a
patientwithknownorsuspected inheritedcardiovasculardisease.
2. Predictive genetic testing in apparently healthy relatives to de-
terminewhohas inherited the family’s causal variant and is at risk
for developing disease.5-11
In both situations, genetic testing should begin in well-
phenotyped individuals, ideally coupled with comprehensive fam-
ily evaluation to aid in interpreting and applying results.
Diagnostic Genetic Testing
Genetic testing can establish a specific, etiologically based diagno-
sis. This testing is particularly helpful in situations in which a rela-
tivelycrudeclinicalphenotype is sharedbymultipleconditions (phe-
nocopies), each with a different underlying cause, prognosis,
treatment, and implications for family. For example, left ventricular
hypertrophy inhypertrophiccardiomyopathymaybedifficult todis-
tinguish from athlete’s heart, hypertensive heart disease, storage
cardiomyopathy (eg, Fabry disease), or infiltrative process (eg, car-
diac amyloidosis). Identifying a pathogenic (disease-causing) GLA
variant in a patient with left ventricular hypertrophy would con-
firmadiagnosis of Fabrydisease andallow for appropriatemanage-
ment, includingscreening fornoncardiacdiseasemanifestationsand
considerationof enzyme replacement therapy. Likewise, determin-
ing thegenetic etiologyof thoracic aortic aneurysms,whichmaybe
amanifestationof syndromicornonsyndromicconditions,may lead
to different thresholds for prophylactic aortic surgery.9
Table 1 lists genetic testing available for the most common in-
herited cardiovascular diseases. In most cases, diagnosis is estab-
lished phenotypically from clinical cardiovascular testing. How-
ever, the presence of a definitively pathogenic variant constitutes
adiagnostic criterion for certainconditions, includingcatecholamin-
ergic polymorphic ventricular tachycardia, Loeys-Dietz syndrome,
andMarfansyndrome.Therefore, identificationofapathogenicvari-
antmay facilitate adiagnosis in cases inwhich clinical diagnostic cri-
teria are not completely fulfilled. An important caveat is that ge-
netic testing isprobabilistic andmaynotyielddefinitivelydiagnostic
results. Results should be correlated with the associated pheno-
type ideally not just in 1 individual but across the family.
Predictive Genetic Testing and Family Evaluation
Formost inherited cardiovascular diseases, the inheritancepattern
is autosomal dominant,with a 50%chance of transmission to each
offspring regardless of sex. Therefore, evaluation of at-risk healthy
familymembers is recommended. The goals of phenotypic and ge-
notypic family evaluations are to identify individuals with previ-
ously unrecognized disease and currently healthy family members
who are at risk for future disease development and require longitu-
dinal follow-up.11 The overall strategy for family screening is sum-
marized in Figure 1. Phenotypic evaluation starts with first-degree
relatives of affected individuals and is repeated periodically be-
cause penetrance (the expression of the clinical phenotype associ-
ated with the causal variant) for some conditions may be delayed
and diagnostic featuresmay notmanifest until adulthood. The fre-
quency and components of longitudinal phenotypic evaluation of
at-risk relatives are based on consensus opinion and vary depend-
ingontheunderlyingcondition.For inheritedcardiomyopathies, lon-
gitudinal evaluationof at-risk relatives typically consistsof, at amini-
mum, echocardiography and electrocardiography repeated every
1 to 5 years based on age (most frequently during adolescence and
young adulthood). Follow-up should be further tailored on the ba-
sis of features relevant to individual relatives or families.
Table 1. Detection Rates and Clinical Utility of Diagnostic Genetic Testing for Selected Inherited
Cardiovascular Diseases
Condition
Major Genes or Gene
Families Analyzeda
Detection
Rate, %b
Utility of Genetic Testing
Diagnostic
Criterion
Effect on
Proband
Management
Predictive
Genetic
Testing
Hypertrophic
cardiomyopathy
Sarcomere genes 30 to >60 NA +c Yes
Dilated cardiomyopathy Sarcomere and
cytoskeleton genes
(including TTN)
30-40 NA NA Yes
LMNA <5 to 10 Yes ++d Yes
Arrhythmogenic
cardiomyopathy
Desmosomal genes ~ 60 Yes + Yes
Long QT syndrome Transmembrane ion
channel genes
50-75 Yes ++ Yes
Catecholaminergic
polymorphic ventricular
tachycardia
RYR2, CASQ2, TRDN,
and CALM1
50-55 Yes ++ Yes
Brugada syndrome SCN5A 20-25 NA + Yes
Marfan syndrome FBN1 >90 Yes ++ Yes
Loeys-Dietz syndrome TGFBR1/2, SMAD3,
and TGFB2/3
70-90 Yes ++ Yes
Familial thoracic aortic
aneurysms and dissections
ACTA2, MYH11, and
MYLK
20-25 NA ++ Yes
Vascular Ehlers Danlos
syndrome
COL3A1 ~ 95 Yes ++ Yes
Familial
hypercholesterolemia
LDLR, APOB, PCSK9,
and LDLRAP1
60-80 Yes ++ Yes
Abbreviations: NA, not applicable;
+may affect management; ++likely
affects management.
a Represents genes or gene families
commonly included on a panel but
not a comprehensive list of all genes
that could potentially be analyzed.
b In general, detection rates are
higher if a family history of the
condition exists.
c Requires differentiating rare
phenocopies such as Fabry disease,
Pompe disease, or cardiac
amyloidosis, with a potential role for
risk assessment.
d Early indication for an implantable
cardioverter defibrillator and/or
transplant referral and a high
likelihood of conduction disease.
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If a definitively pathogenic variant in the family has been iden-
tified, predictive genetic testing can be pursued to identify effi-
ciently which relatives have inherited that variant and which have
not. Relatives confirmed to carry the family’s variant are at risk for
diseasedevelopment.Theyshouldundergoserialphenotypicevalu-
ationandbe informedof the risk for transmission tooffspring.Rela-
tiveswhodonot carry the family’s variant canbe reassuredanddis-
missed from longitudinal phenotypic evaluation but instructed to
seek attention promptly if any clinical change occurs.15,16
Approaches topredictive genetic testing in childrenvary indif-
ferent countries. Concerns center on balancing the potential posi-
tive and negative psychological effects on the child of determining
genotype when the results of testing may not directly change
management.11,17 Predictive genetic testing can also be used for re-
productive planning with prenatal testing during an existing preg-
nancy to determine whether the fetus inherited the causal variant
or through preimplantation genetic diagnosis. Preimplantation ge-
neticdiagnosis identifiesunaffectedembryos, createdusing invitro
fertilization, for implantation to achievepregnancy. Predictive test-
ing in the reproductive context is apersonal decision that should in-
corporate consideration of the collective experience of the family
aswell as thevariablepenetranceandclinical courseassociatedwith
most inherited cardiovascular diseases.
In cases inwhichdiagnostic genetic testing is notperformedor
a causal variant was not identified (results were negative or identi-
fied variants that were not definitively pathogenic), predictive ge-
netic testing for healthy relatives is not available. Serial phenotypic
evaluationbecomes thedefault strategy, typically startingwith first-
degree relatives of affected individuals andexpanding asnewdiag-
noses are made.
When to Test: Recommendations for Using Genetic Testing
Patients newly diagnosedwith an inherited cardiovascular disease
should be offered a comprehensive evaluation, including full phe-
notypic assessment, thorough family history assessment, genetic
counseling and testing, andcoordinated family evaluation. TheBox
summarizes the process of incorporating genetic testing into clini-
cal care. Not all scenarios have equivalent likelihood of leading to a
diagnostic genetic test result. Therefore, identification of situa-
tions that are most likely to yield useful results is important.
High Utility
Adefinitivediagnosis and familial disease increase thepretestprob-
ability of positive genetic test results (identification of a disease-
causing variant). These results can then have a high utility for fam-
ily members who can benefit from predictive testing.18,19
Intermediate Utility
Absenceofa familyhistorydoesnotprecludetheuseofgenetic test-
ing. Genetic forms of cardiovascular disease may be present with-
out affected relatives, owing to recessive inheritance, de novomu-
tations, or reduced penetrance. Genetic testing should still be
considered if results would change the patient’s management or
whenat-risk familymemberswouldbenefit fromtesting. In this situ-
ation, determining with confidence whether a variant is truly the
cause of disease without other affected family members to assess
segregationmay be difficult (Figure 2).
LowUtility
In some scenarios, genetic testing is unlikely to be useful (low like-
lihoodofpositivegenetic test results anda lowpredicted clinical ef-
fect) andshouldbedeferred.Onesuchexample is investigatingsud-
den cardiac death in a family inwhich no living, affected individuals
are available for testing and no DNA is available from affected
decedents.20 Initiation of genetic testing in unaffected relatives is
unlikely to yield informative results andmay provide false reassur-
anceor lead to incorrectdiagnoses.21 Similarly, in situations inwhich
diagnostic genetic testing has identified an ambiguous result, pre-
dictive genetic testing of unaffected relatives is not recommended
because the variant may not be a reliable marker for disease risk.
Figure 1. Flowchart of Family Evaluation and Predictive Genetic Testing
Family proband diagnosed with
inherited cardiovascular disease
Serial phenotypic evaluation of first-degree
relatives of family members found to be affected
during family evaluationa
Genetic testing not performed or results negative
or inconclusive (variant not definitively pathogenic
or of unknown significance)
Diagnostic genetic testing identified
a pathogenic mutation
Predictive genetic testing in at-risk relatives
Serial phenotypic
evaluation to monitor
for disease developmenta
Dismiss from scheduled
screening (perform
evaluation if clinical
change occurs)
At risk for disease
development
Not at increased risk for
disease development
Genotype-negative
relatives
Genotype-positive
relatives
Serial phenotypic evaluation of at-risk first-degree
relatives to monitor for disease developmenta
The approach to family evaluation
after the diagnosis of a genetic
cardiovascular disorder is directed by
whether a definitively pathogenic
variant is found in the family. If so,
predictive genetic testing can be
performed first to identify relatives
who require serial phenotypic
evaluation. If not, first-degree
relatives are recommended to
undergo serial phenotypic evaluation.
a Start and frequency are based on
age and underlying condition.
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Whom to Test and How: Selecting the Right Person
and the Right Genetic Test
Obtainingasystematic familyhistoryandconstructingadetailedpedi-
greeofat least3generationsisanimportantpreludeformanagingfami-
lieswithgeneticdisease (Box).22 This informationwill allowcompre-
hensive assessment of the family’s phenotype and identification of
relativeswhowould benefit frompredictive testing.Whenpossible,
information includedon thepedigree should be confirmedbymedi-
calrecordsor, ideally,byprospectivephenotypicevaluationofrelatives.
Becausemultiplegenetic variantsmaybepresentandact synergisti-
callyorasdiseasemodifiers, resulting inmoreseveredisease,genetic
testing should ideally beginwith the familymemberwho ismost se-
verely affected and has themost definitive diagnosis. This approach
maybe logisticallydifficultowingtogeographyandaccessibilityof the
familybutwillmaximizethelikelihoodofidentifyingallvariantsrelevant
to the phenotype in the family.
Most inherited cardiovascular diseases exhibit genetic hetero-
geneity, with mutations in multiple genes causing the same condi-
tion.Genetic testing for these conditions is accomplishedwithmul-
tigenepanels targeted toaspecificphenotype, suchashypertrophic
cardiomyopathy, or inclusive of a broader array of genes associ-
atedwith a number of different conditions thatmay share overlap-
ping features. For example, current comprehensive panels include
more than 90 genes implicated in different types of cardiomyo-
pathy. These broader tests may be more efficient and cost-
effective when an equivocal phenotype in the family includes fea-
turesofmore than 1 conditionor in familieswithoverlapsyndromes,
for example,members of a familywith coexistinghypertrophic car-
diomyopathy,dilatedcardiomyopathy, and left ventricularnoncom-
paction. When the phenotype is unequivocal, selection of a panel
that is targeted to that particular condition is preferable because
broader panels are unlikely to increase clinical yield andmay intro-
duce ambiguous results.23-25
What the Results Mean: Variant Classification
One of the greatest challenges in multigene panel testing is deter-
mining whether an identified sequence variant is the cause of dis-
ease. In contrast to traditional laboratory testing, genetic testing is
probabilistic in nature26 and classifies variants along a continuum
that reflects the estimated likelihood that a variant causes disease
based on the weight of current evidence. Large-scale population-
sequencing efforts have highlighted the complexity of the human
genome and the remarkable diversity of human genetic variation.
Historically, rare sequence variants without other supporting evi-
dence may have been presumed to be pathogenic. However, in-
sightsgained frompopulation-sequencingeffortshave led to the re-
alization thatmanybenign variants are also rare, prompting amore
conservative approach to variant interpretation.24
The American College of Medical Genetics and Genomics
(ACMG) and the Association for Molecular Pathology27 developed
guidelines for variant interpretation that proposed the following 5
tiers of classification: pathogenic, likely pathogenic, uncertain sig-
nificance, likely benign, andbenign. These classifications drawona
varietyof evidence types, includingpopulation, functional, compu-
tational, and segregation data.27 However, discrepant classifica-
tions exist across laboratories for some variants owing to evolving
knowledge and practice. New tools have been developed to pro-
mote data sharing and improve the interpretation of genetic vari-
ants (ClinVar [https://www.ncbi.nlm.nih.gov/clinvar/] and ClinGen
[https://www.clinicalgenome.org]). Population-sequencing data-
bases, such as the 1000Genomes Project,28 National Heart, Lung,
and Blood Institute Exome Sequencing Project Exome Variant
Server,29 Exome Aggregation Consortium,30 and the Genome Ag-
gregation Database,30 which include exome- or whole-genome–
Box. Steps and Considerations for Incorporating Genetic Testing
Into Clinical Practice
1. Generate a comprehensive, multigenerational (3 generations)
family history to
a. Further understand phenotype in family
b. Identify at-risk healthy relatives needing phenotypic
evaluations
c. Identify affected relatives and severity of their disease
2. Select appropriate patients and families for genetic testing.
Consider
a. Whether family history of the condition exists
b. Testing themost severely affected relative with youngest
onset
c. At-risk healthy relatives whowould benefit from
identification of a causal variant
3. Select appropriate genetic test
a. If diagnosis is established, select test targeted to that
condition
b. Larger panels may be warranted for overlap or ambiguous
phenotypes, with recognition that larger panels may lead to
identification of more variants of uncertain significance
4. Engage in and document a thorough informed consent and
pretest genetic counseling dialogue with patient, including
discussion of
a. Expected yield
b. Probabilistic nature of genetic testing and possible
categories of results
c. Possible influence onmanagement, if any
d. Implications for family members (positive or negative;
consider age also)
e. Potential for variant reclassification
5. Review results and determine appropriate interpretation
a. Read laboratory interpretation and use laboratory support
services
b. Consider looking at the primary data in references, ClinVar,
and other resources
c. Integrate results with knowledge of the patient and family
d. Collaborate with genetics professionals
6. Disclose results and provide and document posttest genetic
counseling
7. Provide writtenmaterials (eg, family letter) or other resources
in lay terms that patients can share with relatives to facilitate
family communication about test results and recommendations
8. Address management of at-risk relatives
a. Consider predictive genetic testing in at-risk relatives if
genetic testing in the family identified a pathogenic or likely
pathogenic variant
b. If genetic testing was not performed or did not identify a
pathogenic or likely pathogenic variant, at-risk relatives may
benefit from periodic phenotypic evaluation
c. If a variant of uncertain significance was identified, consider
genetic testing for segregation in other affected relatives to
further aid in variant interpretation
9. Establish referral network (eg, mental health professionals for
psychology support, specialists for cardiac management,
high-risk obstetricians, and social workers)
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sequencingdata fromindividualsacrossdiverseancestries, aid indis-
tinguishing rare, pathogenic variants frombenignvariants thatmay
be enriched in specific ethnic or racial backgrounds.
Pathogenic and likelypathogenic variants aregenerally consid-
ered to be positive results, meaning that they provide the genetic
etiology for disease (Table 2). These results may be considered for
clinical decisionmaking, includingpredictive genetic testing. Given
the lesser amountof supportingevidenceavailable for likelypatho-
genicvariants, caution iswarrantedwhenusing these results forpre-
dictive genetic testing and the subsequent dismissal of genotype-
negative relatives from care. In contrast, likely benign and benign
variantsaregenerallyconsideredtobenegativeresults,meaningthat
they do not provide a genetic etiology for disease.
Variants of uncertain significance are considered tobe indeter-
minate results that should not be used for clinical decisionmaking.
A variant of uncertain significance does not provide a definitive ge-
netic etiology of disease and should not be used to determine risk
for disease in unaffected relatives. However, testing affected rela-
tives to determine whether the variant segregates with disease in
the family canprovidevaluable evidence to support or dismiss vari-
ant pathogenicity (Figure 2). Segregation analysis involves deter-
mining whether the genetic variant in question is consistently as-
sociatedwith clinical disease in a family. Because the appearanceof
appropriate segregation canoccur by chance (eg, a child has a50%
likelihood of inheriting any particular allele from their parent), data
from a large number of affected relatives or distantly related af-
Figure 2. Predictive Testing and Segregation Testing in a Family to AssistWith Variant Interpretation
Predictive testing for a pathogenic
variant
A
+
+
–
Appropriate cosegregation of a VUSB
+ +
+ +
+ +
Nonsegregation of a VUSC
–
+
Pedigree A shows the use of a pathogenic or likely pathogenic variant identified
in an affected relative (arrowhead) for predictive genetic testing in unaffected
relatives. The son with the variant (white box with + below) is at risk for disease
development, and there is a 50% risk for transmission to each offspring; this
individual should undergo longitudinal follow-up tomonitor for disease
development. The sister without the variant (white circle with − below) is not at
risk for disease development, with no risk to offspring and no need for
longitudinal follow-up unless clinical change is noted. By contrast, when a
variant of uncertain significance (VUS) is identified, segregation testing can be
performed to see whether the variant segregates with disease in the family,
providing evidence of pathogenicity. Pedigree B illustrates segregation of a VUS
with disease in 6 family members, supporting pathogenicity. Pedigree C shows
nonsegregation of a VUS in an affected individual, suggesting that the variant is
not the cause of disease and should not be used for predictive testing. Square
indicates male individual; circle, female individual; filled symbol, clinically
affected; +, variant present; and −, variant absent.
Table 2. Variant Classification Categories and Clinical Implications
Implication
Classification
Benign or
No Varianta Likely Benigna
Variant of Uncertain
Significanceb Likely Pathogenicc Pathogenicc
Meaning No important
variants
detected; genetic
disease cannot
be excluded
Variant detected
is likely to be
harmless;
genetic disease
cannot be
excluded
Ambiguous result;
may be reclassified
if additional
information
becomes available
Likely responsible
for causing
phenotype; family
segregation studies
may provide
additional evidence
for causality
Responsible
for causing
phenotype
Utility for
proband
None None Unknown Likely suggests
diagnosis; may
inform
management or
lead to additional
diagnostic studies
Establishes
diagnosis;
may inform
management
Utility for
family
No option for
predictive
genetic testing;
rely on
longitudinal
phenotypic
evaluation
No option for
predictive
genetic testing;
rely on
longitudinal
phenotypic
evaluation
Should not be used
for predictive
genetic testing;
testing affected
relatives for
segregation may
provide evidence of
causality
Predictive genetic
testing of
unaffected relatives
should be
approached
carefully; may be
combined with
phenotypic
evaluation and
surveillance
Can be used
for predictive
genetic testing
a Result considered to be negative.
bResult considered to be uncertain.
c Result considered to be positive.
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fected relatives provide stronger evidence that the variant causes
disease. On the contrary, observation of a single instance of non-
segregation (a variant of uncertain significance is not present in an
affected relative) indicates that the variant is highly unlikely to be
the cause of disease, assuming the clinical diagnosis of the relative
is not in doubt. Testing affected relatives for segregation aids in the
variant interpretation process; however, it may not affect medical
management in the family unless the variant is reclassified as hav-
ing strong evidence for pathogenicity.
Cautionshouldbeusedwhen interpretingnegativeresults.Even
in cases in which familial disease has been demonstrated, a com-
prehensive panelmay not identify a genetic etiology. Thus, a nega-
tive result doesnot exclude thepossibility of genetic diseasebut in-
dicates that a causative variant could not be identified with the
currently available technology and knowledge. Phenotypic evalua-
tion of at-risk healthy relatives is often still advisable. As technol-
ogyand testofferingsadvance, additional genetic testing in thepro-
bandmay be considered at a subsequent stage.
Furthermore, wemust recognize that variant interpretation is a
dynamicprocessandthatclassificationsmaychangeover timeasad-
ditionalevidenceaboutthevariantbecomesavailable.24,31Laboratory
practices for reportingupdates invariantclassificationdifferandmay
require the clinician to contact the laboratory and the family again to
review the implicationsof updated information. If a variant hasbeen
upgradedtopathogenicor likelypathogenic,predictivegenetic test-
ingmaybeavailable. Ifavarianthasbeendowngradedfrompathogenic
or likely pathogenic tooneof uncertain significance, likely benign, or
benign, genotype-negative relatives whomay have been dismissed
fromcaremust be alerted to their potential risk.
To use genetic testing responsibly, clinicians should be aware
of thecomplex,dynamic, andsometimes inconsistentnatureofvari-
ant interpretation and use the support of genetic testing laborato-
riesandpubliclyavailable resourcessuchasClinVar,ClinGen,andthe
ExomeAggregationConsortium.Ofmost importance, genetic data
must be integratedwith the patient’s findings and family history to
determine the likelihood that a variant is the causeofdisease (Box).
How toOrder Genetic Testing and Important Considerations
Pretestandposttestgeneticcounselingare importantsteps inthege-
netic testingprocess. Suchcounseling is typicallyprovidedby theor-
deringphysicianorgeneticcounselors,specially trainedclinicianswho
facilitate decisionmaking about genetic testing and discuss implica-
tionsof the results for thepatient and family. Pretest counselingpro-
vides the informationnecessary forproper informedconsent, includ-
ing theanticipatedyieldof testing, theprobabilisticnatureofgenetic
testing,howthe resultwill affect thepatient’smedicalmanagement,
implications for familymembers,andthepotential for reclassification
(Box).26 Pretest genetic counseling also gives the opportunity to ex-
plorepotential adversepsychosocial sequela thatcan result fromge-
netictesting,particularlywithpredictivegenetictestingofchildrenfor
diseases that typicallymanifest in adulthood.
Manyof the logistical considerationsofgenetic testinghave im-
proved. Turnaround times are decreasing, with results often avail-
able inweeks insteadofmonths.Genetic testing laboratories are in-
creasingly accepting different sample types as sources of DNA,
including blood, buccal swabs, and saliva. Coverage by third-party
payers, includingMedicareandMedicaid,varies statebystateacross
the United States. Internationally, national health care systems of-
ten provide coverage for genetic testing (eg, Canada, Italy, France,
and theNetherlands); however, this is not universally true (eg,Aus-
tralia).Nonetheless, costs aredecreasing, andmany laboratoriesof-
fer financial assistance programs to contain costs to patients.
The concern about the potential for genetic discrimination for
thosepursuingpredictivegenetic testinghaspreviouslybeen iden-
tified as a disincentive.32 Now, federal laws in many countries are
designed to provide protections against genetic discrimination by
health insurance companies andemployers, suchas theGenetic In-
formationNondiscriminationActof2008 in theUnitedStates.33Al-
though the same legal protection does not exist for life insurance
or long-term care insurance in the United States, protections may
exist in other countries. Therefore, individuals should be informed
of relevant discrimination risks to evaluate their current insurance
coverage before proceeding with testing.
Family Communication
Caring for individualswith inheriteddisease involvesaddressing the
familyasaunit, aparticularconsiderationforgenetic testing.For rela-
tives to access genetic testing, a clear and accurate message must
be relayedto them.Privacy lawspreventclinicians fromdirectly con-
tacting familymembers except in cases of imminent danger; there-
fore, family outreach must be initiated by the patient. When con-
sidering thepotential forpoorpsychosocial functioningowing to the
challengesofadiagnosis,34,35 considerablebarriers toeffectivecom-
munication of genetic information may exist.36 Facilitation of this
communication is the responsibilityof theclinical teamorderingge-
netic testing37 andmay involve theprovisionofmaterialswrittenby
the clinician that explain the results and recommendations for fam-
ilymembers in lay terms (ie, a “family letter”).Developmentofmore
innovative solutions to improve family communication may in-
crease the uptake of family screening and genetic testing.
Future Directions:Whole Exome and Genome Sequencing
Broadertestingplatforms, includingwhole-exomeandwhole-genome
sequencing, arebecoming increasingly available andaffordable and
may play a larger role in clinical care and biomedical investigation.
These tests offer the possibility of discovering new disease genes,
therebyprovidingnew insights intodiseasemechanismsandcausal
pathways. However, owing to the abundance of genetic variation
withinan individualgenome, thechances fordiscoveryarebestwhen
broad genetic testing is coupled with comprehensive phenotypic
evaluationofmultipleaffected relativesorpatient-parent trios toaid
in distinguishing potential causal variants frombackground genetic
variation that is not clinically significant. The yield of novel genedis-
covery is unknown; therefore, this opportunity must be balanced
against thepotential of uncoveringgenetic information that is unre-
lated to the indication for testing. TheACMGrecommended report-
ing incidentally identifiedpathogenicvariants in59genesconsidered
tobemedicallyactionable.38,39Secondaryor incidental findings,such
asarisk forbreastcancer,presentchallengestothe informedconsent
processandmay lead toadditionalphenotypicevaluations tounder-
stand the implicationsof the findings.40Furthermore, theACMG list
includesgenesfor inheritedcardiacconditions, leadingtopossible re-
ferralofpatientstocardiologistsforevaluationofthesecardiac-related
incidentalgenetic findings.Thus,collaborationwithcenterswithspe-
cific expertise in cardiovascular genetics should be strongly consid-
ered to help achieve the best outcomes for patients and families.
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Conclusions
Genetic testing is apowerful tool in thediagnosisof inheritedcardio-
vasculardiseasesand identificationofat-riskhealthyrelatives.Owing
toconstantly increasingavailability, cardiologistsarenowrequiredto
befamiliarwiththemyriadofcomplexitiesandimplicationsforpatients
andfamilies.Whenintegratedeffectively intoclinicalpractice,genetic
testing is an essential step toward individualizedmedicine and, ulti-
mately, effective prevention of cardiovascular disease.
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